Search hospitals
>
Michigan
>
Flint
Genesys Hurley Cancer Institute
Claim this profile
Flint, Michigan 48503
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
448 reported clinical trials
7 medical researchers
Summary
Genesys Hurley Cancer Institute is a medical facility located in Flint, Michigan. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Genesys Hurley Cancer Institute is involved with conducting 448 clinical trials across 473 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.
Area of expertise
Breast Cancer
Genesys Hurley Cancer Institute has run 93 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Genesys Hurley Cancer Institute has run 89 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Tareq Al Baghdadi
Genesys Hurley Cancer Institute
9 years of reported clinical research
Christopher M. Reynolds, MD
Saint Joseph Mercy Hospital
3 years of reported clinical research
Philip J. Stella
Saint Joseph Mercy Hospital
5 years of reported clinical research
Elie G. Dib
Genesys Hurley Cancer Institute
7 years of reported clinical research
Clinical Trials running at Genesys Hurley Cancer Institute
Lung Cancer
Breast Cancer
Breast cancer
Ovarian Cancer
Cancer
Esophageal cancer
Non-Small Cell Lung Cancer
Multiple Myeloma
Gastric cancer
Colorectal Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Durvalumab
for Lung Cancer
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Recruiting
2 awards
Phase 3
8 criteria
Ceralasertib + Durvalumab
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Recruiting
2 awards
Phase 3
10 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Genesys Hurley Cancer Institute?
Genesys Hurley Cancer Institute is a medical facility located in Flint, Michigan. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Genesys Hurley Cancer Institute is involved with conducting 448 clinical trials across 473 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.
Where is Genesys Hurley Cancer Institute located?
The Genesys Hurley Cancer Institute is located at 302 Kensington Ave, Flint, MI 48503.
Who should I call to ask about financial aid or insurance network?
For financial assistance, contact the Financial Assistance Discount Program (FADP) at Genesys Hurley Cancer Institute at (810) 262-9260, Option #5, available Monday-Friday from 8am-5pm. For insurance inquiries, reach out to their insurance service specialists at the same number. The general contact number for the institute is 810-762-8226.
What insurance does Genesys Hurley Cancer Institute accept?
The Genesys Hurley Cancer Institute accepts most U.S. insurances. For coverage confirmation or inquiries, contact your insurance carrier or the Hurley Insurance Specialist Team at (810) 262-9096 (Option #3). Note: Some physician specialists may not participate in your health plan, affecting coverage; uninsured patients may qualify for Hurley Medical Center's discount program.
What awards or recognition has Genesys Hurley Cancer Institute received?
Genesys Hurley Cancer Institute, located in Flint, Michigan, is renowned for its exceptional research and care in the field of oncology. It is a key member of the Michigan Cancer Research Consortium (MCRC), which was awarded a $19.3 million grant by the National Cancer Institute in 2019. This grant supports the MCRC's mission to enhance access to advanced cancer treatments for patients across the community.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.